We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+6.88%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$142M
AUM Growth
-$26.6M
Cap. Flow
-$33.6M
Cap. Flow %
-23.69%
Top 10 Hldgs %
45.91%
Holding
93
New
28
Increased
12
Reduced
11
Closed
39

Top Buys

1
AGN
Allergan plc
AGN
+$6.21M
2
MDVN
MEDIVATION, INC.
MDVN
+$5.39M
3
COO icon
Cooper Companies
COO
+$5.28M
4
BSX icon
Boston Scientific
BSX
+$5.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.11M

Top Sells

1
PRTA icon
Prothena Corp
PRTA
+$4.21M
2
BMY icon
Bristol-Myers Squibb
BMY
+$4.16M
3
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$3.31M
4
ARWR icon
Arrowhead Research
ARWR
+$3.04M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$2.71M

Sector Composition

1 Healthcare 59.79%
2 Technology 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$14.7M 10.35%
+75,000
New +$14.3M
VTRS icon
2
CALL
Viatris
VTRS
$20.1B
$7.73M 5.45%
150,000
+50,000
+50% +$2.46M
AGN
3
DELISTED
Allergan plc
AGN
$6.69M 4.72%
+30,000
New +$6.21M
MDVN
4
DELISTED
MEDIVATION, INC.
MDVN
$6.17M 4.35%
+160,000
New +$5.39M
COO icon
5
Cooper Companies
COO
$14B
$5.42M 3.82%
+160,000
New +$5.28M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$37.3B
$5.24M 3.7%
+100,000
New +$5.11M
BSX icon
7
Boston Scientific
BSX
$65.4B
$5.11M 3.6%
+400,000
New +$5.2M
MDT icon
8
Medtronic
MDT
$106B
$4.78M 3.37%
+75,000
New +$4.56M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$35.7B
$4.74M 3.34%
+75,000
New +$4.46M
CYH icon
10
Community Health Systems
CYH
$465M
$4.54M 3.2%
121,000
+24,200
+25% +$805K
ATRC icon
11
AtriCure
ATRC
$1.77B
$4.14M 2.92%
225,000
+140,000
+165% +$2.33M
INSM icon
12
Insmed
INSM
$23.5B
$4M 2.82%
200,000
+65,000
+48% +$963K
BDSI
13
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.62M 2.55%
+300,000
New +$2.84M
SPNC
14
DELISTED
Spectranetics Corp
SPNC
$3.26M 2.3%
142,600
+92,600
+185% +$2.15M
BRKR icon
15
Bruker
BRKR
$8.86B
$3.15M 2.23%
130,000
+40,000
+44% +$868K
GEVA
16
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$3.14M 2.22%
+30,000
New +$2.55M
TRNX
17
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$2.81M 1.98%
120,000
-10,000
-8% -$208K
COV
18
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$2.71M 1.91%
+30,000
New +$2.24M
ANAC
19
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$2.66M 1.88%
150,000
+130,000
+650% +$2.09M
HCA icon
20
HCA Healthcare
HCA
$82.3B
$2.54M 1.79%
+45,000
New +$2.37M
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.37M 1.67%
10,000
+2,000
+25% +$527K
RNA
22
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$2.21M 1.56%
+175,000
New +$1.42M
ARAY icon
23
Accuray
ARAY
$30.8M
$2.2M 1.55%
250,000
-150,018
-38% -$1.3M
ENTA icon
24
Enanta Pharmaceuticals
ENTA
$400M
$2.15M 1.52%
50,000
+15,000
+43% +$572K
GWPH
25
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.15M 1.51%
20,000
-5,000
-20% -$348K
1
2 3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Ghost Tree Capital held 93 positions worth $142M, down 16% from $168M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ghost Tree Capital withdrew a net $33.6M in Q2 2014, closing 39 positions and reducing 11 holdings. Its most notable exit was Prothena Corp, an estimated $4.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 45% a quarter earlier, followed by Technology.

Against the trend, Ghost Tree Capital opened a new position in Allergan plc worth $6.69M.

  • Ghost Tree Capital's largest Q2 2014 buy was Allergan plc: 30,000 shares worth $6.69M.
  • Ghost Tree Capital added most to AtriCure in Q2 2014, an estimated $2.33M increase.
  • Ghost Tree Capital's biggest Q2 2014 reduction was Avadel Pharmaceuticals, cutting an estimated $2.71M.
  • Ghost Tree Capital fully exited Prothena Corp in Q2 2014, selling an estimated $4.21M.
  • Ghost Tree Capital's ten largest holdings make up 46% of its $142M portfolio in Q2 2014.
  • Ghost Tree Capital opened 28 new positions and closed 39 in Q2 2014.
  • Ghost Tree Capital's portfolio value fell 16% quarter-over-quarter to $142M.

Based on Ghost Tree Capital's 13F filing for Q2 2014, filed 14 Aug 2014.